C2N is pioneering novel, intelligent ways to develop drugs against brain disorders at a more rapid pace and lower cost than conventional methods. In addition, we are commercializing point-of-care diagnostics to enable early detection of conditions like Alzheimer’s disease (AD). We are firm believers that early detection of disease will prove essential for effective disease modification.